Amphastar Pharmaceuticals, Inc.
AMPH
$17.50
-$0.95-5.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.38% | -2.07% | 1.60% | -2.77% | 8.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.38% | -1.83% | 0.33% | -4.38% | -0.76% |
| Cost of Revenue | 18.26% | -2.44% | 4.39% | 0.80% | 4.33% |
| Gross Profit | -17.51% | -1.13% | -3.23% | -9.12% | -5.38% |
| SG&A Expenses | 7.51% | 14.50% | 17.03% | 8.65% | 11.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.24% | 4.33% | 6.90% | 3.97% | 7.60% |
| Operating Income | -63.45% | -21.13% | -15.12% | -23.60% | -22.32% |
| Income Before Tax | -67.43% | -27.41% | -54.88% | -21.71% | -34.76% |
| Income Tax Expenses | -34.88% | 24.79% | -42.61% | -32.45% | 35.17% |
| Earnings from Continuing Operations | -74.61% | -35.65% | -57.09% | -18.23% | -41.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.61% | -35.65% | -57.09% | -18.23% | -41.44% |
| EBIT | -63.45% | -21.13% | -15.12% | -23.60% | -22.32% |
| EBITDA | -45.04% | -14.74% | -11.21% | -16.92% | -16.54% |
| EPS Basic | -73.30% | -32.76% | -55.11% | -14.82% | -40.74% |
| Normalized Basic EPS | -65.77% | -24.13% | -2.10% | -18.46% | -33.97% |
| EPS Diluted | -72.55% | -31.02% | -52.56% | -12.33% | -37.04% |
| Normalized Diluted EPS | -65.03% | -21.03% | 1.78% | -15.33% | -30.68% |
| Average Basic Shares Outstanding | -4.87% | -4.31% | -4.42% | -4.00% | -1.18% |
| Average Diluted Shares Outstanding | -6.88% | -8.08% | -8.07% | -7.53% | -5.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |